To increase the stem cell content of T cell-depleted bone marrow transplants (BMT), we treated 12 patients with hematological malignancies with BMT from HLA-identical sibling donors given G-CSF 10 g/kg/day for 5 days before marrow harvest. After CD34 
more than 2 ϫ 10 6 CD34 + cells/kg. However, it remains to be determined whether the larger doses of T cells given in the PBPC transplants increase the risk of chronic graftversus-host disease (GVHD). 5 Furthermore, attempts to reduce the T cell dose of the PBPC transplant have paradoxically increased the incidence of acute GVHD. 6 Another approach to increase the CD34 + cell dose without a corresponding increase in lymphocyte dose would be to harvest G-CSF-stimulated bone marrow. Recent studies indicate that G-CSF-stimulated bone marrow harvests confer rapid and sustained hematological recovery after autologous 7, 8 and allogeneic 9, 10 BMT. Adequate stem cell collections are of critical importance if physical methods of T cell depletion are performed because of the high cell loss during manipulation. We previously showed that T cell depletion by elutriation resulted in significant stem cell losses associated with increased transplant-related mortality in patients receiving CD34
+ cell doses Ͻ10 6 /kg. 11 In order to improve the stem cell content of T cell-depleted BMT, we therefore evaluated the use of bone marrow collected following 5 days of G-CSF administration to enhance marrow cellularity and CD34 + cell content. 12, 13 We measured hematological recovery and early post-transplant outcome in a series of 12 patients with hematological malignancies and compared the results with a historical transplant group matched for disease type and CD34 + cell dose. Our results indicate that G-CSF, despite increasing the CD34 + cell content of T cell-depleted marrow harvests, does not result in earlier engraftment and carries a risk of delayed pancytopenia.
Patients and methods

Patients
Between June 1996 and December 1996, 12 patients with hematologic malignancies received a BMT from an HLAidentical sibling. Patients were treated under National Institutes of Health protocols 93-H-0212 (chronic myeloid leukemia (CML)), and 94-H-0092 (acute leukemia and myelodysplastic syndrome (MDS)) approved by the local Institutional Review Board. Recipient age ranged between 17-46 years (median, 30). Eight had CML, six in chronic phase (CP), and two in blastic phase (BP). Three patients had myelodysplastic syndrome in transformation (tMDS), and one was in second remission of acute lymphoblastic leukemia. Details of diagnosis, transplant procedure and outcome are shown in Table 1 .
Preparative regimen
Eleven patients received cyclophosphamide 60 mg/kg/day on day Ϫ7 and Ϫ6 before BMT, followed by eight fractions of total body irradiation to a total of 1360 cGy. One patient (UPN 50) with MDS following Fanconi anemia received cyclophosphamide 10 mg/kg/day days Ϫ7 and Ϫ6, followed by three fractions of total body irradiation totalling 450 cGy days Ϫ5 to Ϫ3 and fludarabine 25 mg/m 2 /day days Ϫ5 to Ϫ2.
G-CSF administration, donor marrow collection and T cell depletion
Donors received 10 g/kg G-CSF s.c daily, starting day Ϫ4 pretransplant. The fifth dose was given on the day of marrow collection (day 0). Daily blood counts were obtained during G-CSF administration and donors were seen daily for possible side-effects. A total volume of 1.2 l of marrow was harvested under general anesthesia from the posterior iliac crests providing at least 2-4 × 10 8 nucleated cells/kg recipient weight. In order to prevent clotting, 16 000 units of preservative-free heparin was added to the collection bag at the beginning of the harvest and again after the collection of the first 500 ml. The bone marrow was concentrated using an automated or manual mononuclear cell concentration procedure before further processing. A CD34 + cell selection system (Ceprate SC; CellPro Inc, Bothell, WA, USA) was used according to the manufacturer's instructions to enrich for CD34 + cells and CML = chronic myeloid leukemia; CP = chronic phase; BP = blast phase; tMDS = myelodysplasia in transformation; FA = Fanconi anemia; ALL = acute lymphoblastic leukemia; CR = complete remission; A/W = alive and well; AmphoB = amphotericin B; RSV = respiratory syncytial virus. a TR = GVHD occurring before T cell add-back, AB = GVHD occurring after T cell add-back (seven patients).
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Became pancytopenic after remission induction with daunorubicin (2 days) and cytosine arabinoside (5 days).
deplete the product of T cells. 14 Our goal was to provide a minimum of 1.0 ϫ 10 6 /kg CD34 + cells and no more than 5 ϫ 10 5 /kg CD3 + lymphocytes. For the first two collections, we observed substantial cell loss during processing associated with an increased tendency of the G-CSF-stimulated marrow to clump. Subsequently, the processing was modified by adding acid citrate dextrose solution A, 10% by volume (ACD-A; Baxter, Deerfield, IL, USA). This measure reduced, but did not eliminate, the tendency for these marrow collections to clump.
Flow cytometry
CD34
+ cells were quantitated using acquisition and analysis strategies previously described. 15 Cells were labelled with fluorescein-conjugated anti-CD71 (PharMingen, San Diego, CA, USA), peridinin chlorophyl protein-conjugated anti-CD45 (Becton Dickinson, San Jose, CA, USA), and phycoerythrin-conjugated anti-CD34 (Becton Dickinson) or an IgG1 isotype control (PharMingen). Acquisition of 100 000 cells was performed using either a Becton Dickinson FACScan or FACSort flow cytometer. The total nucleated cell population was defined as cells staining with either anti-CD45 or anti-CD71 on corrected cell counts.
GVHD prophylaxis
Patients received cyclosporine 3 mg/kg i.v., starting on day Ϫ4 until an oral dose was tolerated. Doses were adjusted to maintain a cyclosporine plasma level between 200-400 g/ml. Cyclosporine was continued at least to day 180 post-BMT, and longer if chronic GVHD developed.
T cell add-back
To reconstitute immune function and graft-versus-leukemia effects, 1 × 10 7 CD3 + cells/kg fresh donor mononuclear cells, obtained by leukapheresis on day 45, were given. However, grade уII acute GVHD developing before day 45 was a contraindication to lymphocyte transfusions.
Post-transplant management
All patients received fluconazole and norfloxacin until day 30 for antifungal and antimicrobial prophylaxis followed by bactrim weekly from day 30 to 180 as prophylaxis against pneumocystis infection. Patients also received high-dose acyclovir as prophylaxis against cytomegalovirus (CMV) and herpes virus reactivation. 16 CMV antigen was monitored weekly until day 100 post-BMT, and ganciclovir, at an initial dose of 5 mg/kg i.v. q 12 h for the first 10 days followed by 5 mg/kg three times a week, with high-dose immunoglobulin was given, when there was evidence of CMV reactivation. 17 Acute GVHD grade II was treated with high-dose steroids (0.5-1.0 g/m 2 daily) for 3 days, tapered according to response. Patients not responding within 10 days were considered steroid-resistant and received ATG 15 mg/kg daily for at least 10 days. Chronic GVHD was treated with combinations of low-dose prednisolone (10-30 mg/day) and cyclosporine daily or alternate days.
Historical controls
Hematological recovery and major outcome variables were compared with a group of previously described historical controls treated under the same protocols between September 1993 and May 1996 who received bone marrow T cell-depleted by elutriation but without prior G-CSF stimulation.
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Statistical analysis
Comparisons of different variables between G-CSF-stimulated marrow recipients and historical controls were made using Fisher's exact test for discontinuous variables and Wilcoxon's single rank sum test for continuous variables. The Student's t-test was used to compare differences between blood counts. Actuarial probabilities of diseasefree survival and CMV reactivation were calculated by the method of Kaplan and Meier. 18 Differences between outcomes were compared using Peto and Peto's modification of Wilcoxon's rank-sum analysis.
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Results
G-CSF donor stimulation and bone marrow harvest
Donors tolerated G-CSF treatment well with only lowgrade fever, bone pain and headache which ceased after marrow harvesting. The bone marrow harvest procedure was rapid. In most cases it was possible for two operators to collect 1 l of marrow during a 30-min period. Donors reported no untoward side-effects occurring following the harvest and no donor developed thrombocytopenia less than 120 × 10 9 /l. Four patients developed pancytopenia after initial engraftment, and were found to have hypocellular bone marrow biopsies. UPN 52 transplanted from his sister for MDS showed initial engraftment but remained transfusiondependent and required G-CSF to maintain granulocyte counts greater than 1 ϫ 10 9 /l. The bone marrow on day 55 showed 10% cellularity but chromosome analysis confirmed 100% donor karyotype. After 14 days of G-CSF, the marrow cellularity had improved and there was hematopoiesis in all cell lines. Nevertheless, he remained dependent on transfusions and died on day 100 from a bacterial meningitis. In UPN 60 the cytopenia was transient and resolved without G-CSF administration. The remaining two (UPN 53, 56) progressed to bone marrow aplasia and received a boost of G-CSF-mobilized peripheral blood progenitor cells (PBPC) from the original donor on days 91 and 133. Two of these patients survive with full donor hematopoiesis -one after PBPC rescue and one after spontaneous recovery. The third patient died of progressive RSV pneumonia 3 days after the PBPC boost (Table 1) .
Marrow processing
Comparison with non-G-CSF-stimulated BMT
Because of the pancytopenia observed in this series, a comparison was made with a historical patient group treated under the same protocols but receiving T cell-depleted marrow not stimulated by G-CSF. Figure 1 shows the distribution of CD34 + cell dose in the G-CSF-stimulated marrow and the historical group. Twenty-four of 42 patients from
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Hematological recovery:
The mean maximum neutrophil, monocyte and lymphocyte count achieved each week for the first 14 weeks following BMT was calculated for the 24 historical controls and the 11 patients in the G-CSF group (Figure 2a-c) . The initial recovery of neutrophils and monocytes was identical, but G-CSF-stimulated marrow recipients showed a decline in counts after 8 weeks which differed significantly from the controls. In contrast there was no difference in lymphocyte counts at any time post-BMT. Figure 3 shows the proportion of evaluable patients requiring transfusion of platelets ( Figure 3a ) and red cells (Figure 3b ) during the first 14 weeks post-transplant. Although early transfusion requirements were comparable for G-CSF-stimulated bone marrow recipients and the historical controls, there was a trend for increased platelet and red cell transfusions for the G-CSF-stimulated group beyond week 10 post-transplant.
Platelet and red cell recovery:
CMV reactivation, G-CSF usage and pancytopenia:
Compared with the historical controls, patients receiving G-CSF-stimulated marrow had a lower probability of CMV reactivation which occurred later after BMT (Figure 4 ). The effect of gancyclovir treatment as well as the late occurrence of cytopenia is also reflected in the proportion of patients requiring G-CSF support in the first 14 weeks posttransplant ( Figure 5 ). However, four of 11 patients compared with 0/24 controls developed either severe or transient delayed pancytopenia (P = 0.006) ( Table 3) . Although not having received ganciclovir, UPN 52 had incomplete engraftment for platelets and red cells, and was transfused until he died on day 100 of bacterial meningitis complicating grade IV acute GVHD. Bone marrow karyotype on day 55 was 100% donor (female). UPN 53 engrafted and subsequently received ganciclovir and later foscarnet three times a week for CMV reactivation. His counts decreased and became aplastic on day 85. He was infused with G-CSF-stimulated T cell-replete PBPC from his original donor without reconditioning and his counts slowly recovered 1 month later. UPN 56 developed RSV pneumonia on day 116 requiring mechanical ventilation and treatment
G-CSF-modified BMT improves CD34
+ cell content DA Mavroudis et al 435 Table 3 Characteristics of recipients of G-CSF-stimulated and non-G-CSF-stimulated marrow with ribavirin. On day 128 she became aplastic and received G-CSF-stimulated T cell-replete PBPC from her original donor, before she died on day 136 with multisystem failure. Bone marrow karyotype on day 100 was 100% donor (male). UPN 60 had good initial engraftment and became transfusion-independent for several weeks before her counts started to drop on day 78. Then she became neutropenic and required 6 units of red cells until her counts slowly recovered 2 weeks later. Bone marrow karyotype on day 100 was 100% donor (male).
G-CSF BMT no G-CSF BMT P
Major outcome variables:
Disease-free survival in the first 180 days is compared in Figure 6 for all 12 G-CSF-stimulated marrow recipients, and historical controls receiving greater (n = 24) or less (n = 18) than 10 6 CD34 + cells/kg. The survival of the G-CSF-stimulated marrow recipients did not differ from the controls receiving Ͼ10 6 CD34 + cells/kg but survival for patients receiving Ͻ10 6 CD34 + cells/kg was significantly inferior to both groups receiving higher stem cell doses (P = 0.01).
Discussion
The goal of our experimental BMT program is to devise ways to independently control the components of the allograft in order to optimize hematopoietic and immunological recovery. The first step to separately reconstitute hematopoiesis and immune function was to T cell-deplete the marrow by elutriation and add-back measured doses of donor lymphocytes after a delay of 30-45 days. 20 The results of this study showed that the elutriation technique resulted in considerable CD34
+ cell losses and did not always result in adequate T cell depletion. We found that patients receiving Ͼ10
6 CD34 + cells/kg had a significantly lower transplantrelated mortality and a superior disease-free survival when compared with patients receiving lower CD34 + cell doses.
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In order to increase the stem cell content and improve the reproducibility of T cell depletion, we gave donors G-CSF for 5 days to stimulate and increase marrow progenitor cells. This procedure resulted in a shorter period of general anesthesia for the donors and was well tolerated. The harvested marrow was depleted of T cells by positive selection of CD34 + cells. The CD34 + cell yield exceeded the target of 10 6 /kg on 11 out of 12 occasions and CD3
+ cell doses of Ͻ5 ϫ 10 5 /kg were achieved in all cases. Twelve patients received T cell-depleted, G-CSF-stimulated marrow. Although engraftment occurred in all cases, it was incomplete in three patients and four patients developed pancytopenia between 2-3 months following BMT. This followed a short course of ganciclovir in UPN 53, 56 and 60, and occurred without administration of any prior myelosuppressive agents in UPN 52. The pancytopenia appeared to be due to graft failure since in three informative patients developing pancytopenia, we documented the marrow to be donor type indicating that the cytopenia was not due to graft rejection. Furthermore three cytopenic patients had already developed aGVHD and a booster transplant of G-CSF-mobilized PBPC restored hematopoiesis without further preconditioning in UPN 53.
Because of the unexpected finding of late pancytopenia, we compared hematological recovery and major transplant outcome variables with a group of patients matched for CD34 + cell dose but receiving unstimulated bone marrow depleted of T cells by elutriation. These historical controls were well matched for age, diagnosis, donor-recipient sex and T cell dose (Table 3) . We found that although early recovery of neutrophils and monocytes was comparable between G-CSF-stimulated and non-stimulated transplants, there was a significant decline in the neutrophil and mono- cyte (but not lymphocyte) count in the G-CSF-stimulated marrow recipients from the 8th week after BMT. A similar trend for increased transfusion requirements was observed for the G-CSF group beyond week 10 post-transplant ( Figure 3 ). The occurrence of late cytopenias may have been compounded by gancyclovir-induced myelosuppression. However the G-CSF group received less ganciclovir than the historical controls, who were not subject to profound pancytopenia (Figure 4) . Apart from an apparent increase in G-CSF usage on week 8, the pattern of G-CSF requirement was comparable in the two groups ( Figure 5 ).
Since the CD34 + cell doses in the G-CSF-stimulated and unstimulated marrow, donations were comparable and the initial harvest volumes identical, the differences in hematopoietic recovery observed could be attributed to differences in the functional characteristics of the CD34 + population in the two groups. Perhaps a lower percentage of the CD34 + cells in the G-CSF-primed marrow were the most primitive long-term repopulating cells. The observed recovery followed by a later decline of hematopoiesis suggests that G-CSF-stimulated marrow provided sufficient engrafting cells that were nonetheless deficient in self-renewal and thus long-term repopulation. Since it is known that G-CSFmobilized PBPC transplants appear to establish sustained hematopoietic reconstitution, it is possible that the marrow becomes depleted of early progenitors during G-CSF treatment. Several animal studies suggest that cytokines can shift early repopulating stem cells out of the marrow into the peripheral blood. Using the rigorous functional stem cell competitive repopulation assay, Bodine and coworkers 21 found that after 5 days of stem cell factor/G-CSF treatment, mice had only 1/4 of the baseline long-term repopulating stem cells in the marrow, and three times the baseline stem cells shifted to the peripheral blood. Interestingly, bone marrow stem cell activity rebounded to 10-18 times baseline 2 weeks after cessation of cytokines. Thus this time point may be better for collection of primed bone marrow cells, supported by more recent data from primate studies. 22 It is also possible that the technique used to select CD34 + cells may have contributed to the results observed: Unlike the elutriation procedure, the CD34 + positive selection may have depleted a more primitive CD34-negative stem cell population which has been described in mice and primates, but not yet in humans. [23] [24] [25] However there are no other reports of late pancytopenia following T cell depletion using this method with unstimulated marrow harvests.
In contrast to our results, other reports using G-CSFstimulated marrow for autologous or allogeneic BMT have been generally encouraging. Janssen et al 7 reported in preliminary results of a prospective randomized trial of G-CSF-stimulated autologous PBSC or BM transplants that hematopoietic recovery was the same in both groups and concluded that the speed of engraftment reflected the activated status of the stem cells and not the anatomic compartment from which they derive. However, the engraftment was rather delayed in both groups, and the PBPCs were collected after 7-8 days of G-CSF treatment, which may not be optimal. Also, in the autologous setting, endogenous recovery may have masked late graft failure. On the other hand, Hansen et al 8 found that despite an apparent increase of myeloid progenitors harvested after G-CSF stimulation, the engraftment kinetics of G-CSF-stimulated autologous bone marrow transplants were no different from historical controls. Preliminary reports of G-CSF stimulation of the donors prior to bone marrow harvest, suggest that engraftment is complete and stable following allogeneic T cell-replete BMT. 9, 10 Furthermore, in another study where patients received G-CSF-stimulated T cell-replete bone marrow grafts with or without the addition of donor CD34 + cell-enriched PBPC, there was an accelerated engraftment compared to historical controls and no additional benefit from the combined use of PBPC and bone marrow. 26 Since engraftment is a function of both stem cell and T cell dose, either can independently influence transplant outcome. 27 Although delayed cytopenia was not found by others, our study concerns T cell-depleted BMT. The possibility therefore exists that our results reflect T cell depletion further compromising engraftment by a defective stem cell inoculum.
Despite the delayed cytopenia encountered in this series, it should be noted that it was possible to rescue patients using G-CSF-mobilized unmanipulated PBPC and no patient died directly from marrow failure. Disease-free survival was closely comparable to that of the control group receiving high CD34 + cell doses and significantly greater than the group of historical controls who received less than 10 6 /kg CD34 + cells. Thus the approach was successful in achieving CD34
+ cell doses Ͼ10 6 /kg in 11/12 cases and this translated into the superior disease-free survival also observed in the subset of historical controls receiving higher stem cell doses. However, until the mechanism of the delayed pancytopenia is better understood, it would be prudent to avoid the use of T cell-depleted G-CSF-stimulated marrow.
